Clinical Trials
69 trialsRICE
University of Cologne
Durvalumab(MEDI4736)/Tremelimumab in Combination With Gemcitabine/Cisplatin in Chemotherapy-naïve Biliary Tract Cancer
Seoul National University Hospital
Neoadjuvant CCRT With Gemcitabine/Durvalumab (MEDI4736) Followed by Adjuvant Gemcitabine/Durvalumab(MEDI4736) in Resectable or Borderline Resectable Pancreatic Cancer
Seoul National University Hospital
Biomarker-oriented Study of Durvalumab (MEDI4736) in Combination With Olaparib and Paclitaxel in Gastric Cancer
Seoul National University Hospital
AZD6738 Plus Durvalumab in Biliary Tract Cancer
Seoul National University Hospital
DDR-Umbrella Study of DDR Targeting Agents in Advanced Biliary Tract Cancer
Seoul National University Hospital
PREDICT
University Medical Center Groningen
Durvalumab Combined With Surufatinib as Maintenance Therapy in Patients With Advanced Biliary Tract Cancer
China Medical University, China
To Evaluate the Efficacy of Durvalumab + Anlotinib in Terms of OS and PFS.
Shanghai Chest Hospital
Durvalumab and Lenvatinib With or Without Chemotherapy in First-Line Treatment of Advanced Biliary Tract Cancer
Peking Union Medical College Hospital
UPSTREAM
European Organisation for Research and Treatment of Cancer - EORTC
Combining ICI With SBRT or HypoFrx-RT for ES NSCLC
Xuanwu Hospital, Beijing
Radiomic Signature as Predictive Marker of Response to Chemoradiation and Durvalumab in Stage III NSCLC.
Fondazione IRCCS Policlinico San Matteo di Pavia
DEDALUS
Fondazione IRCCS Policlinico San Matteo di Pavia
Radiotherapy Combined With ICIs as Treatment for LA-NSCLC After Failing Induction Immunochemotherapy
Zhejiang Cancer Hospital
WIRE
Cambridge University Hospitals NHS Foundation Trust
PANDORA
AUSL Romagna Rimini
VIVA
Ospedale Policlinico San Martino
ESPADURVA
University Hospital, Essen
ILLUMINATE
University of Sydney
Mechanism of Response to IMFINZI Neoadjuvant Therapy in Non-small Cell Lung Cancer Patients Based on Multiple-omics Models
Peking Union Medical College Hospital
MILES-5
National Cancer Institute, Naples
RADIANT
Ottawa Hospital Research Institute
Window of Opportunity Trial of Durvalumab (MEDI4736) or Durvalumab/Tremelimumab as Neoadjuvant Chemotherapy to Identify Immune Dynamics in Surgically Resectable Head and Neck Cancer Patients.
Yonsei University
Immunological Variables Associated to ICI Toxicity in Cancer Patients
Jules Bordet Institute
Microbiome Immunotherapy Toxicity and Response Evaluation
Cambridge University Hospitals NHS Foundation Trust
QUASAR
University of California, San Diego
Durvalumab Plus Lenvatinib as First-line Treatment for Unresectable Hepatocellular Carcinoma
Zhejiang University
Durvalumab Combined With GemCis Neoadjuvant Therapy of Resectable Intrahepatic Cholangiocarcinoma With High Recurrence Risk
Tianjin Medical University Cancer Institute and Hospital
Durvalumab Combined With Chemotherapy Neoadjuvant Therapy of Biliary Tract Cancer
Tianjin Medical University Cancer Institute and Hospital
Vactosertib and Durvalumab in Gastric Cancer
National Cancer Center, Korea
BOLD
ARCAGY/ GINECO GROUP
This Study is a Phase II Study of AZD6738 in Combination With Durvalumab in Patients With Solid Tumor (Cohort A (N=30): GC Who Have Failed Secondary Chemotherapy Treatments Regimen; Cohort B (B=30): Melanoma Patients Who Have Failed to IO)
Samsung Medical Center
An Open-label, Phase I/II Study of PLENA Regimen in Patients With Unresectable Pancreatic Cancer or BTC
Chinese PLA General Hospital
Safety,Tolerability,and Efficacy of VCN-01 With Durvalumab in R/M Head and Neck Squamous Cell Carcinoma
Institut Català d'Oncologia
Efficacy of Durvalumab in Non-muscle-invasive Bladder Cancer
Hellenic GenitoUrinary Cancer Group
IDEAR
Instituto Portugues de Oncologia, Francisco Gentil, Porto
An Open Label, Multicenter Phase 2 Study of Durvalumab (MEDI4736) + Olaparib as Maintenance Therapy in Chinese
Sun Yat-sen University
Neoadjuvant LDRT Combined With Durvalumab in Potentially Resectable Stage III NSCLC
Sichuan Cancer Hospital and Research Institute
Durvalumab With Chemotherapy Followed by Sequential Radiotherapy for Limited Stage Small Cell Lung Cancer
Beijing Haidian Hospital
Gut Microbiota Reconstruction for NSCLC Immunotherapy
Shanghai Zhongshan Hospital
Durvalumab Plus Tremelimumab Combined With Proton Therapy for HNSCC
Samsung Medical Center
A Study to Evaluate the Safety of Concurrent Durvalumab With CRT Followed by Durvalumab for Chinese Unresectable Stage III NSCLC
Shandong Cancer Hospital and Institute
The Efficacy of Hepatic Arterial Infusion Chemotherapy (HAIC) Combine Lenvatinib and Durvalumab (HILL) in Advanced Hepatocellular Carcinoma (HCC)
Sun Yat-sen University
Radiotherapy Plus Durvalumab in Elderly Esophageal Squamous Cell Carcinoma
ChineseAMS
DUREC
Grupo Espanol Multidisciplinario del Cancer Digestivo
SBRT and Durvalumab for Inoperable/Unresectable Hepatocellular Carcinoma
The University of Hong Kong
The Combination Therapy of TACE and Ablation With Durvalumab in Hepatocellular Carcinoma at Intermediate Stage (TAD)
Fudan University
An uMbrella Study of BIomarker-driven Targeted Therapy In Patients With Platinum-resistant Recurrent OvariaN Cancer(AMBITION)
Yonsei University
DOMEC
Leiden University Medical Center